Leukopenia occurring after kidney transplantation is a very dangerous condition. It may increase the risk of severe infections which might lead to septicemia or may result in graft loss because the dose of immunosuppressants must be reduced, so it must be diagnosed and treated as soon as possible. The use of recombinant granulocyte colony-stimulating factor (G-CSF) in renal transplant recipients is a new therapeutic approach. This factor is successful in producing a rise in neutrophil count without adverse effect on renal function. We report the successful use of G-CSF in a renal transplant recipient in whom neutropenia developed following pulmonary fungal infection.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Percutaneous Nephrostomy in Kidney Transplant Recipients: Incidence, Risk Factors, Complications and Outcomes.
Nephrology (Carlton)
January 2025
Department of Transplant, Mayo Clinic Florida, Jacksonville, Florida, USA.
Ureteral stenosis is a frequent complication after kidney transplantation, causing significant morbidity and potential graft function impairment. Treatment options include conservative management, endourological procedures, surgical interventions and percutaneous nephrostomy (PCN). While PCN effectively relieves obstruction, it comes with its own complications.
View Article and Find Full Text PDFDonor-derived cell-free DNA in chronic lung allograft dysfunction phenotypes: a pilot study.
Front Transplant
December 2024
Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), Department of CHROMETA, KU Leuven, Leuven, Belgium.
Long-term survival after lung transplantation is limited due to chronic lung allograft dysfunction (CLAD), which encompasses two main phenotypes: bronchiolitis obliterans syndrome (BOS) and restrictive allograft syndrome (RAS). Donor-derived cell-free DNA (dd-cfDNA) is a biomarker for (sub)clinical allograft injury and could be a tool for monitoring of lung allograft health across the (pre)clinical spectrum of CLAD. In this proof-of-concept study, we therefore assessed post-transplant plasma dd-cfDNA levels in 20 CLAD patients (11 BOS and 9 RAS) at three consecutive time points free from concurrent infection or acute rejection, during stable condition, preclinical CLAD, and established CLAD ( = 3 × 20 samples).
View Article and Find Full Text PDFBK polyomavirus (BKV) causes polyomavirus-associated nephropathy (PyVAN) and polyomavirus-associated hemorrhagic cystitis (PyVHC) following kidney transplantation and allogeneic hematopoietic stem cell transplantation (HST). BKV strains fall into four distinct genotypes (BKV-I, -II, -III, and -IV) with more than 80% of individuals are seropositive against BKV-I genotype, while the seroprevalence of the other four genotypes is lower. PyVAN and PyVHC occurs in immunosuppressed (e.
View Article and Find Full Text PDFTacrolimus to belatacept conversion in proteinuric kidney transplant recipients.
Front Immunol
December 2024
Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA, United States.
Background: Proteinuria is associated with worse allograft outcomes in kidney transplant recipients (KTRs) and treatment strategies are limited. We examined the outcomes of calcineurin inhibitor (CNI) to belatacept conversion in proteinuric KTRs.
Methods: In a pilot phase II single-arm multicenter prospective trial, we recruited adult KTRs >6 months post-kidney transplantation with an estimated glomerular filtration rate (eGFR) ≥30 ml/min/1.
The impact of medication regimen complexity on patient-related and clinical outcomes in kidney failure: a systematic review.
Expert Opin Pharmacother
January 2025
School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Introduction: Kidney failure is a life-limiting condition that profoundly impacts an individual's quality of life. The significant medication burden on patients required to manage the comorbidities and complications of kidney failure can have implications for patient-reported and clinical outcomes.
Methods: This work systematically reviewed methods used to assess medication regimen complexity amongst adults with kidney failure, the associated patient-reported and clinical outcomes, and the effectiveness of interventions to address regimen complexity.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!